iBio Inc. stock falls Tuesday, underperforms market | news.google.com • |
iBio Inc. stock falls Tuesday, underperforms market | news.google.com • |
iBio Inc. stock falls Tuesday, underperforms market | news.google.com • |
iBio Inc. stock outperforms market despite losses on the day | news.google.com • |
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update | news.google.com • |
iBio Inc. stock rises Friday, outperforms market | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-25 | 2024-06 | -0.46 | N/A | N/A | N/A |
2024-05-13 | 2024-03 | 0 | -0.71 | N/A | N/A |
2024-02-09 | 2023-12 | 0 | -2.42 | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -4.2 | N/A | N/A |
2023-10-10 | 2023-06 | 0 | N/A | N/A | N/A |
2023-07-06 | 2023-03 | 0 | N/A | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-10-31 | BRENNER MARTIN | Chief Executive Officer | 182.50K | Sale |
2014-09-16 | DESANTIS CARL R | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-03-30 | DURAN FELIPE | Chief Financial Officer | 39.63K | Stock Award(Grant) |
2020-08-10 | EASTERN CAPITAL LTD | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2020-06-03 | ERWIN ROBERT L | President | 108.11K | Sale |
2020-03-18 | ISETT THOMAS FRANCIS III | Chief Executive Officer | 1.27M | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 512.28K | 312.49K | 1.86% |
2023-06-29 | Avantax Planning Partners, Inc. | 155.00K | 94.55K | 0.56% |
2023-06-29 | Blackrock Inc. | 137.94K | 84.14K | 0.50% |
2023-06-29 | Bank Of New York Mellon Corporation | 87.47K | 53.36K | 0.32% |
2023-06-29 | Geode Capital Management, LLC | 76.29K | 46.53K | 0.28% |
2023-06-29 | Renaissance Technologies, LLC | 46.10K | 28.12K | 0.17% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 336.21K | 205.09K | 1.22% |
2023-06-29 | Vanguard Extended Market Index Fund | 165.75K | 101.11K | 0.60% |
2023-05-30 | Fidelity Extended Market Index Fund | 46.85K | 32.80K | 0.17% |
2023-05-30 | Fidelity Total Market Index Fund | 13.73K | 9.61K | 0.05% |
2023-05-30 | Fidelity Series Total Market Index Fund | 9.49K | 6.64K | 0.03% |
2023-06-29 | Vanguard Institutional Index-Inst Total Stock Market Ind | 7.28K | 4.44K | 0.03% |
Split | Date |
---|---|
1 : 20 | 2023-11-29 |
1 : 25 | 2022-10-10 |
1 : 10 | 2018-06-11 |
-
IBIO is all over the Twitter..
-
From Seeking Alpha
IBIO Stock Pops On COVID-19 Vaccine Development Update
In the press release, iBio provided an update surrounding one of its proprietary vaccine candidates for the protection of infection from the SARS-CoV-2 virus, the virus that causes COVID-19.
In the release, the company reminded investors that it is investigating an array of adjuvants in combination with its proprietary lichenase carrier molecule. This molecule is fused to a coronavirus sbunit protein. Of course, the goal here is to prove that this technology is safe and effective in preventing viral infection and the development of COVID-19.
In particular, IBIO is developing the vaccine as a potential option for the most vulnerable populations, including the elderly.
Importantly, the company said that it has completed ten distinct preclinical study arms for the IBIO-21 antigen-adjuvant combinations. The preclinical results show that the combinations included were delivered via intramuscular and intranasal routes, with datasets now under evaluation.
So far, the company knows that anti-SARS-CoV-2 spike titers to IBIO-201 were observed 21 days after immunization. Moreover, titers continued to increase over the course of the 42-day study. Also, IBIO said that favorable Th1 and Th2 immune profiles were observed in these preclinical studies.
The company also went on to explain that early functional testing of mice demonstrates the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2 in ex vivo assays.
As a result of the positive data thus far, the company is planning to conduct additional testing of IBIO-201 antisera, including further evaluations of neutralizing titers in multiple formats. The company also said that significant immune profiling studies are ongoing to evaluate the safety and immune protection correlates, including anti-specific T cell responses and memory B cell testing.
This additional testing is taking place surrounding both candidates, IBIO-201 and IBIO 200, under a collaboration with the Texas A&M University System of laboratories. In a statement, Tom Isett, Chairman and CEO at iBio, had the following to offer:
WE ARE ENCOURAGED BY THESE PRE-CLINICAL DATA, WHICH DEMONSTRATE IBIO-201’S ABILITY TO GENERATE AN IMMUNE RESPONSE TO SARS-COV-2 SEQUENCES AND NEUTRALIZE PROTEIN INTERACTION. WE EXPECT TO GAIN MORE INSIGHT AS WE COMPLETE DATA ANALYSIS OF BOTH OF OUR COVID-19 VACCINE CANDIDATES.
-
Where are all the rocket ships now ? Sunk faster then the Titanic.
-
Lesson learned: I will never do the same mistakes again I did with KBIO (2015), MRNA (2020) and NVAX (2020). Long is the answer! Higher risk but better reward!!!
-
https://alphastocknews.com/ibio-ibio-stock-heads-up-on-covid-19-vaccine-update/3926/
It is everywhere, expect 10$ hit very quick this weeeeeeeeek!!!!
-
Back to 3.80
-
Lol well that lasted 8 mins should of never bought this
-
-
Something is going software are missed up, red but green, numbers are not matching even in fidelity. The hackers are around the corners!!!
-
We are encouraged by these pre-clinical data, which demonstrate IBIO-201’s ability to generate an immune response to SARS-CoV-2 sequences and neutralize protein interaction,” said Tom Isett, Chairman & CEO of iBio. “We expect to gain more insight as we complete data analysis of both of our COVID-19 vaccine candidates.”
-
Comes from a “Plant” is the subject.
If he is referring to a manufacturing then that is too generic and he does not need to mention anymore as we already knew those. There are too many drug manufacturers.
So think - it is the Plant he is referring
-
From Motley Fool
Aug-7thiBio currently has two COVID-19 vaccine candidates in preclinical testing: IBIO-200 and IBIO-201. The company expects to be able to produce between 200 million and 700 million doses per year of IBIO-200. iBIO's FastPharming platform could also potentially help it win contract manufacturing deals to make other COVID-19 vaccines.
Several programs in clinical development rely on iBio's FastPharming technology, including early-stage vaccine candidates targeting H5N1 and H1N1 flu, anthrax, and malaria. iBio's own internal pipeline features one animal health program in clinical development: IBIO-400, an experimental vaccine for classical swine fever.
In addition, iBio is evaluating IBIO-100 in preclinical testing as a potential treatment for fibrotic disease. The experimental drug already received Orphan Drug Designation from the Food and Drug Administration for treating systemic scleroderma, a rare autoimmune disorder.
-
-
Remember there is No Vaccine that it can be done just in few months... if there is that would be scary..
Plant vaccine maybe Yes! But drugs now way as most of those vaccine takes years and years of studies and trials before it can be proven to human.
-
Think about this guys
At 3.8 if you have $20K to buy
You gonna get 5,263 shares
What is the difference between 3.8 and 0?
0 is BK where I dont think it will happen.
Let say it goes down to 0.5 that means 3.3 difference and your money is approximately $2,632. Your share still the same and you wont loose anything as long as you kept it. 3.3 delta is very small going down the bottom.
Now, what about going up?
Huge opportunity the delta is very large....At 10 your $20K can go up to $52,630 this easy to hit once good news is out. I saw this a lot.
What about at 20 your $20K can go up to $105,260
What about 30, 40, 50, 100, 200 like the rest?
Remember the ceiling has plenty of room unlike going down as we are almost in the bottom.
So huge!!!!
-
So seriously if this thing drop down again on Monday or any day next week. I will trim down my MRNA, NVAX and BNTX gain 500 shares each and load it here!!!
Will see.. I am waiting for this although I am even now and No loss yet on average as I kept adding every time it is down. I will do the same as I did on SRNE and ALT where I started in the bottom and still owned 75% of my original buyin.
-
I aint sellin this thing, so sad where I sold Groupon and Roku for a big loss and then suddenly these stocks move big! I cant buy back this these before because all the losses will be a gain and washed out!
This is the importance of holding your stock and stick to the plan.
-
Boy that hurts for you losers who didnt know when to pull the plug at 6$ plus.
-
iBio Inc. stock falls Tuesday, underperforms market
news.google.com • -
iBio Inc. stock falls Tuesday, underperforms market
news.google.com • -
iBio Inc. stock falls Tuesday, underperforms market
news.google.com • -
iBio Inc. stock outperforms market despite losses on the day
news.google.com • -
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update
news.google.com • -
iBio Inc. stock rises Friday, outperforms market
news.google.com • -
iBio Inc. stock rises Thursday, still underperforms market
news.google.com •